Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 26, 2025 07:00 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

Fourth-quarter and full-year 2024 Rezdiffra net sales of $103.3 million and $180.1 million, respectivelyAs of year-end 2024, more than 11,800 patients on Rezdiffra Reports cash, cash equivalents,...
February 26, 2025 06:30 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

Patients achieved a mean 6.7 kPa reduction in liver stiffness as measured by vibration-controlled transient elastography (VCTE); this represents the largest reduction in liver stiffness reported in a...
February 21, 2025 08:00 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference

CONSHOHOCKEN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the 45th Annual TD Cowen Health Care...
February 12, 2025 08:00 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025

CONSHOHOCKEN, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its fourth-quarter and full-year 2024 financial results...
January 13, 2025 06:45 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra

Preliminary fourth-quarter and full-year 2024 Rezdiffra™ (resmetirom) net sales ranges of $100 million to $103 million and $177 million to $180 million, respectivelyPreliminary year-end 2024 cash,...
January 03, 2025 08:00 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CONSHOHOCKEN, Pa., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference...
November 06, 2024 08:00 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences

CONSHOHOCKEN, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in fireside chats at three upcoming investor...
October 31, 2024 07:00 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates

Third-quarter 2024 net sales of $62.2 million Rezdiffra™ (resmetirom) coverage goal achieved early, with more than 80 percent of commercial lives covered; less than 5 percent of Rezdiffra-covered...
October 30, 2024 08:00 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting®

CONSHOHOCKEN, Pa., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic...
October 21, 2024 08:00 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis

Positive results from the MAESTRO-NASH OUTCOMES study could make resmetirom the first medication approved for patients with compensated NASH cirrhosis, a population at high risk of progressing to...